Friday, 16 October 2026European Markets

GLINTT Stock Jump On Thursday, Outperforms Market

Loading stream...

(VIANEWS) - The Market ended the session with GLINTT (GLINT.LS) rising 9.94% to €0.38 on Thursday, after two sequential sessions in a row of losses. PSI rose 2.23% to €6,184.88, following the last session's downward trend on what was an all-around bullish trend exchanging session today.

GLINTT's last close was €0.34, 14.77% higher than its 52-week high of €0.30.

About GLINTT

Glintt - Global Intelligent Technologies, S.A. provides IT and consulting services in Portugal and internationally. The company offers business consulting services, such as pharmacy management, continuous, diagnostic, and project consulting; and IT consulting services, including applications and technology consulting, business process management, and data analytics. It also provides IT infrastructure services comprising cloud and datacenter, service and application management, networking and security, and information security; physical design and automation, and software solutions; and integrated application and equipment support services. The company primarily serves the healthcare, pharma, financial services, and telecommunications markets, as well as the public sector. Glintt - Global Intelligent Technologies, S.A. was incorporated in 1995 and is based in Sintra, Portugal.

Earnings Per Share

As for profitability, GLINTT has a trailing twelve months EPS of €0.04.

PE Ratio

GLINTT has a trailing twelve months price to earnings ratio of 9.4. Meaning, the purchaser of the share is investing €9.4 for every euro of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 4.84%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 9.4%, now sitting on 115.18M for the twelve trailing months.

Earnings Before Interest, Taxes, Depreciation, and Amortization

GLINTT's EBITDA is 12.5.

More news about GLINTT (GLINT.LS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com